- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05616676
En kort kognitiv opgaveintervention for NHS-personale berørt af COVID-19-traume (GAINS-2-undersøgelse) (GAINS-2)
En randomiseret kontrolleret afprøvning af en kort kognitiv opgaveintervention for at støtte NHS-personale, der oplever påtrængende minder om traumatiske hændelser fra arbejdet i COVID-19-pandemien.
Frontline sundhedspersonale er ofte udsat for traumatiske hændelser på arbejdet (f.eks. at se patienter dø), forstærket af COVID-19-pandemien. En betydelig del oplever påtrængende minder om disse begivenheder, der pludselig dukker op i tankerne: de kan forstyrre funktionen og kan bidrage til posttraumatisk stresslidelse. Tidligere forskning har vist, at en kort adfærdsintervention kan reducere antallet af påtrængende minder efter en traumatisk begivenhed. I denne undersøgelse vil vi teste effekten af en digital billedkonkurrerende opgave, en digital musiklytteopgave og behandling som sædvanlig (TAU) for National Health Service (NHS) personale med påtrængende minder om arbejdsrelaterede traumatiske hændelser fra pandemien. Vi tester effekten på antallet af påtrængende erindringer (primært udfald) og andre kliniske symptomer (PTSD, angst, depression og søvnløshed) foruden arbejdsfunktion, generel funktion og livskvalitet (sekundære udfald). Interventionsgennemførlighed, acceptabilitet og implementering vil også blive undersøgt (yderligere resultater). Vi vil rekruttere cirka 150 NHS-medarbejdere (via Intensive Care Society, sociale medier og direkte annoncer fra NHS Trusts) med påtrængende minder om traumatiske begivenheder oplevet under COVID-19-pandemien.
Undersøgelsen er finansieret af Wellcome Trust (223016/Z/21/Z).
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
En statistisk analyseplan vil blive udarbejdet forud for den første interimanalyse ved brug af Bayesianske analyser til statistisk inferens.
Regelmæssig overvågning vil blive udført af P1vital Products for at verificere, at undersøgelsen er udført, og data genereres, dokumenteres og rapporteres i overensstemmelse med protokollen, GCP og de gældende lovkrav. Kvalitetssikringsrepræsentanter fra sponsoren kan udføre en audit af undersøgelsen i overensstemmelse med lovgivningsmæssige retningslinjer og relevante standarddriftsprocedurer.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Oxfordshire
-
Wallingford, Oxfordshire, Det Forenede Kongerige, OX10 8BA
- P1vital Products Ltd
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Beskrivelse
Inklusionskriterier:
- 18 år eller derover.
- Kan læse, skrive og tale på engelsk.
- Arbejdede i en klinisk rolle med COVID-19 patienter i NHS under COVID-19 pandemien.
- Oplevet mindst én traumatisk hændelse relateret til deres kliniske arbejde under COVID-9-pandemien opfylder kriterium A i Diagnostic and Statistical Manual of Mental Disorders, 5. udgave (DSM-5) kriterier for Post-Traumatic Stress Disorder (PTSD): "eksponering" til faktisk eller truet død, alvorlig skade eller seksuel vold" ved "direkte at opleve den eller de traumatiske begivenheder" eller "personligt overvære begivenheden(erne), som den opstod for andre".
- Oplev påtrængende minder om den eller de traumatiske begivenheder.
- Oplevede mindst tre påtrængende minder i ugen før screeningen.
- Har internetadgang.
- Villig og i stand til at give informeret samtykke og gennemføre undersøgelsesprocedurer
- Villig og i stand til at blive kontaktet af forskerholdet i studieperioden.
- Har ikke deltaget i en tidligere undersøgelse af denne intervention fra dette forskerhold
Ekskluderingskriterier:
• Har færre end tre påtrængende minder i løbet af indkøringsugen.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Kort digital billedkonkurrerende opgave
Adgang til en kort digital billedkonkurrerende opgave i 24 uger (første 4 uger med valgfri forskerstøtte).
|
Første session guidet af en forsker: Et huskestik efterfulgt af at spille et computerspil med mentale rotationsinstruktioner. Mulighed for at deltage i selvadministrerede/guidede sessioner efter den første session. |
|
Eksperimentel: Kort digital musiklytteopgave
Adgang til en kort digital musiklytteopgave i 24 uger (første 4 uger med valgfri forskersupport).
|
Første session guidet af en forsker: Information om komponistens musik efterfulgt af lytning til klassisk musik. Mulighed for at deltage i selvadministrerede/guidede sessioner efter den første session. |
|
Eksperimentel: Behandling som sædvanlig
Adgang til rutinemæssig behandling, som deltagerne ellers ville modtage, hvis de havde påtrængende minder om traumatiske hændelser i 24 uger.
|
Adgang til rutinemæssig pleje, som deltagere ellers ville modtage, hvis de har påtrængende minder om traumatiske hændelser.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Intrusive Memories of Traumatic Event(s)
Tidsramme: Run-in/screening week, Week 4 (all arms)
|
Number of intrusive memories of traumatic event(s) recorded by participants in a brief daily online diary for 7 days.
|
Run-in/screening week, Week 4 (all arms)
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Søvntilstandsindikator (SCI)
Tidsramme: Baseline, 4 uger, 12 uger og 24 uger (alle arme)
|
Denne skala med 2 punkter måler søvnproblemer i forhold til DSM-5-kriterierne for søvnløshed.
Genstandssvar er hver scoret 0-4, med score fra 0 til 2, der angiver tærskelkriterier for søvnløshed.
Samlet score spænder fra 0-8, hvor en højere score indikerer bedre søvn.
|
Baseline, 4 uger, 12 uger og 24 uger (alle arme)
|
|
Number of Intrusive Memories of Traumatic Event(s)
Tidsramme: Run-in/Screening week, Weeks 12 and 24 (all arms)
|
Number of intrusive memories of traumatic event(s) recorded by participants in a brief daily online diary for 7 days.
|
Run-in/Screening week, Weeks 12 and 24 (all arms)
|
|
PTSD Checklist for DSM-5 (PCL-5)
Tidsramme: Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
|
This 20-item measure assesses symptoms of PTSD over the last week.
Items are rated on a 5-point scale ranging from 0 ("not at all") to 4 ("extremely").
Scores are summed to give a total severity score (ranging 0 to 80), with greater scores indicating greater symptom severity.
|
Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
|
|
Generalised Anxiety Disorder 2-item Scale (GAD-2)
Tidsramme: Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
|
This 2-item short-form self-report measure assesses symptoms of anxiety.
Items are rated for how often they have bothered the respondent over the last two weeks, from 0 ("not at all") to 3 ("nearly every day").
Total score is the sum of both items and ranges from 0 to 6, with greater scores indicating greater symptom severity.
|
Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
|
|
Patient Health Questionnaire 2-item Version (PHQ-2)
Tidsramme: Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
|
This 2-item short-form self-report measure assesses symptoms of depression.
Items are rated for how often they have bothered the respondent over the last two weeks, from 0 ("not at all") to 3 ("nearly every day").
Total score is the sum of both items and ranges from 0 to 6, with greater scores indicating greater symptom severity.
|
Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
|
|
Scale of Work Engagement and Burnout (SWEBO) - Work Engagement Total Score
Tidsramme: Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
|
This 19-item self-report measure assesses work engagement and burnout.
The work engagement subscale consists of 10 items assessing three dimensions (vigour, attentiveness, dedication).
The burnout subscale consists of 9 items assessing three dimensions (exhaustion, disengagement and inattentiveness).
Respondents rate how often they have felt each descriptive in the past two weeks, from 1 (not at all) to 4 (all the time).
The work engagement subscale total score is calculated as a mean of items (range 1-4), with greater scores indicating greater work engagement.
|
Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
|
|
Scale of Work Engagement and Burnout (SWEBO) - Work Burnout Total Score
Tidsramme: Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
|
This 19-item self-report measure assesses work engagement and burnout.
The work engagement subscale consists of 10 items assessing three dimensions (vigour, attentiveness, dedication).
The burnout subscale consists of 9 items assessing three dimensions (exhaustion, disengagement and inattentiveness).
Respondents rate how often they have felt each descriptive in the past two weeks, from 1 (not at all) to 4 (all the time).
The work burnout subscale total score is calculated as a mean of items (range 1-4), with greater scores indicating greater work burnout.
|
Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
|
|
Sickness Absence
Tidsramme: Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
|
Single item assessing self-reported number of sick days taken from work in the last 4 weeks.
|
Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
|
|
Intention to Leave Job
Tidsramme: Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
|
3 items assess participants' intention to leave their job e.g.
"I think a lot about leaving the job", each rated from 1 (strongly agree) to 5 (strongly disagree).
The total score ranges 3 to 15, with a lower score indicating stronger intention to leave the job.
|
Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
|
|
5-level European Quality of Life 5 Dimension (EQ-5D-5L), Mobility
Tidsramme: Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
|
The 5-level version of the EuroQol-5D (EQ-5D-5L) is a brief, five-item measure for assessing general quality of life and health status.
Items assess mobility, self-care, usual activities, pain/discomfort and anxiety/depression each on a 5-point scale.
The mobility item is scored on a 5-point ordinal scale from "I have no problems in walking about" to "I am unable to walk about".
|
Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
|
|
5-level European Quality of Life 5 Dimension (EQ-5D-5L), Self Care
Tidsramme: Baseline, Week 4, Week 12 and Week 24
|
The 5-level version of the EuroQol-5D (EQ-5D-5L) is a brief, five-item measure for assessing general quality of life and health status.
Items assess mobility, self-care, usual activities, pain/discomfort and anxiety/depression each on a 5-point scale.
The self care item is scored on a 5-point ordinal scale from "I have no problems washing or dressing myself" to "I am unable to wash or dress myself".
|
Baseline, Week 4, Week 12 and Week 24
|
|
5-level European Quality of Life 5 Dimension (EQ-5D-5L), Usual Activities
Tidsramme: Baseline, Week 4, Week 12 and Week 24
|
The 5-level version of the EuroQol-5D (EQ-5D-5L) is a brief, five-item measure for assessing general quality of life and health status.
Items assess mobility, self-care, usual activities, pain/discomfort and anxiety/depression each on a 5-point scale.
The usual activities item is scored on a 5-point ordinal scale from "I have no problems doing my usual activities" to "I am unable to do my usual activities".
|
Baseline, Week 4, Week 12 and Week 24
|
|
5-level European Quality of Life 5 Dimension (EQ-5D-5L), Pain / Discomfort
Tidsramme: Baseline, Week 4, Week 12 and Week 24
|
The 5-level version of the EuroQol-5D (EQ-5D-5L) is a brief, five-item measure for assessing general quality of life and health status.
Items assess mobility, self-care, usual activities, pain/discomfort and anxiety/depression each on a 5-point scale.
The pain / discomfort item is scored on a 5-point ordinal scale from "I have no pain or discomfort" to "I have extreme pain or discomfort".
|
Baseline, Week 4, Week 12 and Week 24
|
|
5-level European Quality of Life 5 Dimension (EQ-5D-5L), Anxiety / Depression
Tidsramme: Baseline, Week 4, Week 12 and Week 24
|
The 5-level version of the EuroQol-5D (EQ-5D-5L) is a brief, five-item measure for assessing general quality of life and health status.
Items assess mobility, self-care, usual activities, pain/discomfort and anxiety/depression each on a 5-point scale.
The anxiety / depression item is scored on a 5-point ordinal scale from "I am not anxious or depressed" to "I am extremely anxious or depressed".
|
Baseline, Week 4, Week 12 and Week 24
|
|
5-level European Quality of Life 5 Dimension (EQ-5D-5L), Overall Health
Tidsramme: Baseline, Week 4, Week 12 and Week 24
|
The 5-level version of the EuroQol-5D (EQ-5D-5L) is a brief measure for assessing general quality of life and health status.
Respondents rate their overall health today on a visual analogue scale from 0 (the worst health you can imagine) to 100 (the best health you can imagine).
|
Baseline, Week 4, Week 12 and Week 24
|
|
World Health Organization Disability Assessment Schedule 12-item Version (WHODAS 2.0)
Tidsramme: Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
|
The 12-item, self-report version of the WHODAS 2.0 will be used to assess difficulties in relation to the impact of intrusive memories.
Respondents rate how much difficulty they have had in each area in the past 30 days, from 0 (none) to 4 (extreme or cannot do).
The overall score is calculated as a percentage of the maximum possible score (i.e., 48 points), with greater scores indicating greater impairment.
|
Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
|
|
Intrusive Memory Ratings: Item 1. Approximately How Often Did Intrusive Memories of the Traumatic Event Pop Into Your Mind?
Tidsramme: Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
|
This questionnaire assesses a number of intrusive memories characteristics, including frequency (Item 1: 7-point categorical response from 'never' to 'many times a day'); distress (Item 2: 0=not at all to 10=extremely); disruption to concentration (Item 3: 0=not at all to 10=extremely); interference (Item 4: how much (0=not at all to 10=extremely), and Item 4a: for how long (6-point response from '<1min' to '>60mins')); impact on work functioning (Item 5: how much (0=not at all to 10=extremely) and Item 6: in what ways (open text response)); impact on functioning in other areas of life (Item 7: how much (0=not at all to 10=extremely) and in what ways (Item 8: open text response)). Here we present Item 1 assessing the frequency of intrusive memories on a 7-point scale from 'never' to 'many times a day'. Other items from this questionnaire are presented below. |
Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
|
|
Intrusive Memory Ratings: Item 4a. Duration of Interference
Tidsramme: Baseline, Week 4, Week 12 and Week 24 (all arms)
|
This questionnaire assesses a number of intrusive memories characteristics, including frequency (Item 1: 7-point categorical response from 'never' to 'many times a day'); distress (Item 2: 0=not at all to 10=extremely); disruption to concentration (Item 3: 0=not at all to 10=extremely); interference (Item 4: how much (0=not at all to 10=extremely), and Item 4a: for how long (6-point response from '<1min' to '>60mins')); impact on work functioning (Item 5: how much (0=not at all to 10=extremely) and Item 6: in what ways (open text response)); impact on functioning in other areas of life (Item 7: how much (0=not at all to 10=extremely) and in what ways (Item 8: open text response)). Here we present Item 4a assessing the for how long intrusive memories interfered with what participants were doing on a 7-point scale from '<1 min' to '>60 mins'. Other items from this questionnaire are presented below. |
Baseline, Week 4, Week 12 and Week 24 (all arms)
|
|
Intrusive Memory Ratings: Distress (Item 2), Disruption to Concentration (Item 3), Interference (Item 4), Impact on Work Functioning (Item 5), and Impact on Functioning in Other Areas of Life (Item 7)
Tidsramme: Baseline, Week 4, Week 12 and Week 24 (all arms)
|
This questionnaire assesses a number of intrusive memories characteristics, including frequency (Item 1: 7-point categorical response from 'never' to 'many times a day'); distress (Item 2: 0=not at all to 10=extremely); disruption to concentration (Item 3: 0=not at all to 10=extremely); interference (Item 4: how much (0=not at all to 10=extremely), and Item 4a: for how long (6-point response from '<1min' to '>60mins')); impact on work functioning (Item 5: how much (0=not at all to 10=extremely) and Item 6: in what ways (open text response)); impact on functioning in other areas of life (Item 7: how much (0=not at all to 10=extremely) and in what ways (Item 8: open text response)). Here we present data for the five items scored on an 11-point scale (0=not at all to 10=extremely) assessing distress (Item 2), disruption to concentration (Item 3), interference (Item 4), impact on work functioning (Item 5), and impact on functioning in other areas of life (Item 7). |
Baseline, Week 4, Week 12 and Week 24 (all arms)
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Changes to Health and Work - Dichotomous Outcomes
Tidsramme: 4 weeks, 12 weeks and 24 weeks (all arms)
|
The 9-item questionnaire will be used to assess the occurrence and number of any new traumatic events, any additional stressful life events (e.g.
relationship problems, financial problems), new treatments received, untoward medical occurrences, changes to the job, or changes to the number of hours worked per week since the last assessment.
Dichotomous outcomes are presented below, and discrete outcomes with count data are presented under "Changes to health and work - discrete outcomes".
|
4 weeks, 12 weeks and 24 weeks (all arms)
|
|
Changes to Health and Work - Discrete Outcomes
Tidsramme: 4 weeks, 12 weeks and 24 weeks (all arms)
|
The 9-item questionnaire will be used to assess the occurrence and number of any new traumatic events, any additional stressful life events (e.g.
relationship problems, financial problems), new treatments received, untoward medical occurrences, changes to the job, or changes to the number of hours worked per week since the last assessment.
Discrete outcomes are presented below, and dichotomous outcomes are presented under "Changes to health and work - dichotomous outcomes".
|
4 weeks, 12 weeks and 24 weeks (all arms)
|
|
Feedback Questionnaire
Tidsramme: After 4 weeks (brief imagery-competing task and brief music listening task arms only)
|
A 12-item questionnaire assessing participants' experience of using the brief cognitive task.
The first ten items assess how easy, helpful, distressing, burdensome and acceptable participants found the brief cognitive task, how willing they would be to use it in the future, how confident they would be in recommending it to a friend and how much they feel it could be used to support staff within the NHS, each rated from 0 (not at all) to 10 (very).
The last two items ask how the brief cognitive task could be improved, and for any other comments or suggestions about the brief cogntive task, both with an open response.
|
After 4 weeks (brief imagery-competing task and brief music listening task arms only)
|
|
Feedback Questionnaire (Total Score)
Tidsramme: After 4 weeks (brief imagery-competing task and brief music listening task arms only)
|
A 12-item questionnaire assessing participants' experience of using the brief cognitive task.
The first ten items assess how easy, helpful, distressing, burdensome and acceptable participants found the brief cognitive task, how willing they would be to use it in the future, how confident they would be in recommending it to a friend and how much they feel it could be used to support staff within the NHS, each rated from 0 (not at all) to 10 (very); items for distress and burden are reverse scored from 0 (very) to 10 (not at all).
The last two items ask how the brief cognitive task could be improved, and for any other comments or suggestions about the brief cognitive task, both with an open response.
A total score of the eight categorical items is presented (range 0 - 80), with greater scores indicating more favourable feedback towards the allocated digital task.
|
After 4 weeks (brief imagery-competing task and brief music listening task arms only)
|
|
Optional Qualitative Interview
Tidsramme: Week 4 and Week 24 (brief imagery competing task and brief music listening task arms only)
|
This semi-structured interview will consist of a number of questions designed to gain an in-depth understanding of participants' experience of using the brief cognitive task, including acceptability, improvement suggestions, and potential barriers/facilitators to implementation.
|
Week 4 and Week 24 (brief imagery competing task and brief music listening task arms only)
|
|
Weekly Work Pattern, Number of Days Worked
Tidsramme: Baseline, Week 4, Week 12 and Week 24
|
One item asses the number of days worked in the last week (both with responses from 0 to 7 days).
|
Baseline, Week 4, Week 12 and Week 24
|
|
Weekly Work Pattern, Number of Night Shifts Worked
Tidsramme: Baseline, Week 4, Week 12 and Week 24
|
One item asses the number of night shifts worked in the last week (both with responses from 0 to 7).
|
Baseline, Week 4, Week 12 and Week 24
|
|
Expectancy of Intervention Effect (Credibility and Expectancy Questionnaire, CEQ) - Categorical Items
Tidsramme: Day 0 (post-randomisation)
|
The Credibility and Expectancy Questionnaire (CEQ) consists of 6 items.
Items 1, 2, 3, and 5 were assessed on a 9-point integer scale ranging from 1 ("not at all") to 9 ("very").
Items 4 and 6 were assessed on an 11-point scale (response range of 0-100%) and, for comparability, were converted to the same 9-point scale as other items.
CEQ total score was calculated by summing all six items producing a possible total score range of 6-54; with greater scores indicating greater credibility and expectancy of intervention effect.
Participants completed the Credibility and Expectancy Questionnaire (CEQ) after being informed of treatment allocation (Day 0).
|
Day 0 (post-randomisation)
|
|
Expectancy of Intervention Effect (Credibility and Expectancy Questionnaire, CEQ) - Total Score
Tidsramme: Day 0 (post-randomisation)
|
The Credibility and Expectancy Questionnaire (CEQ) consists of 6 items.
Items 1, 2, 3, and 5 were assessed on a 9-point integer scale ranging from 1 ("not at all") to 9 ("very").
Items 4 and 6 were assessed on an 11-point scale (response range of 0-100%) and, for comparability, were converted to the same 9-point scale as other items.
CEQ total score was calculated by summing all six items producing a possible total score range of 6-54; with greater scores indicating greater credibility and expectancy of intervention effect.
Participants completed the Credibility and Expectancy Questionnaire (CEQ) after being informed of treatment allocation (Day 0).
|
Day 0 (post-randomisation)
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Studieleder: Emily Holmes, Uppsala University (UU), Sweden
- Ledende efterforsker: Amy Beckenstrom, P1vital Products, Wallingford
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- P1V-GAINS-IN02
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
IPD-delingstidsramme
IPD-delingsadgangskriterier
Anonymiserede forskningsdata vil blive gjort tilgængelige på OSF på ubestemt tid.
OSF er en open source-webapplikation, der er frit tilgængelig for offentligheden og det videnskabelige samfund.
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- ANALYTIC_CODE
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Kort digital billedkonkurrerende opgave
-
Assistance Publique - Hôpitaux de ParisRekrutteringOndine syndrom | Medfødt centralt hypoventilationssyndrom (CCHS)Frankrig